Related references
Note: Only part of the references are listed.MUC1 triggers lineage plasticity of Her2 positive mammary tumors
Zhi Pang et al.
ONCOGENE (2022)
Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations
Shuo Yang et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
Source and Impact of the EGF Family of Ligands on Intestinal Stem Cells
Helen E. Abud et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Caveolin-1: a multifaceted driver of breast cancer progression and its application in clinical treatment
Xian-Ling Qian et al.
ONCOTARGETS AND THERAPY (2019)
HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity
Shiying Wu et al.
NATURE CELL BIOLOGY (2019)
The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?
Lorenzo Castagnoli et al.
CANCERS (2019)
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
Jacqulyne P. Robichaux et al.
CANCER CELL (2019)
HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study
Altuna Halilovic et al.
SCIENTIFIC REPORTS (2019)
The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab
Jung Won Shin et al.
BIOMOLECULES (2019)
The landscape of d16HER2 splice variant expression across HER2-positive cancers
Chiara Costanza Volpi et al.
SCIENTIFIC REPORTS (2019)
Mutant p53 gain of function induces HER2 over-expression in cancer cells
A. A. Roman-Rosales et al.
BMC CANCER (2018)
HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3
Ana Ruiz-Saenz et al.
CANCER RESEARCH (2018)
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
Amanda N. Fader et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
NCCN Guidelines® Insights Non- Small Cell Lung Cancer, Version 5.2018 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy
Patricia M. R. Pereira et al.
NATURE COMMUNICATIONS (2018)
The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature
Yu-ying Lei et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2017)
Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature
Fausto Petrelli et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Validation of OncoPanel A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer
Elizabeth P. Garcia et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2017)
Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes
A. Sveen et al.
ONCOGENE (2016)
Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing
Qi Chen et al.
NATURE IMMUNOLOGY (2016)
HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy
Albina Stocker et al.
PLOS ONE (2016)
Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells
Zhike Chen et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2015)
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
Emanuele Valtorta et al.
MODERN PATHOLOGY (2015)
Updated Meta-analysis on HER2 Polymorphisms and Risk of Breast Cancer: Evidence from 32 Studies
Wei Chen et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)
P95 HER2 fragments and breast cancer outcome
Deniz Tural et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2014)
Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells
D. Raina et al.
ONCOGENE (2014)
Mutation of the palmitoylation site of estrogen receptor α in vivo reveals tissue-specific roles for membrane versus nuclear actions
Marine Adlanmerini et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts
Suling Liu et al.
STEM CELL REPORTS (2014)
Identification of Caveolin-1 as a Potential Causative Factor in the Generation of Trastuzumab Resistance in Breast Cancer Cells
Sreeja C. Sekhar et al.
JOURNAL OF CANCER (2013)
Systematic Review and Meta-analysis of the Influence of HER2 Expression and Amplification in Operable Oesophageal Cancer
David S. Y. Chan et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2012)
Matrix metalloproteinase-2 Promotes αvβ3 Integrin-Mediated Adhesion and Migration of Human Melanoma Cells by Cleaving Fibronectin
Yang Jiao et al.
PLOS ONE (2012)
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2
Heidi Greulich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Integration of ERα-PELP1-HER2 signaling by LSD1 (KDM1A/AOF2) offers combinatorial therapeutic opportunities to circumventing hormone resistance in breast cancer
Idriss M. Bennani-Baiti
BREAST CANCER RESEARCH (2012)
High- and Low-Affinity Epidermal Growth Factor Receptor-Ligand Interactions Activate Distinct Signaling Pathways
Jordan A. Krall et al.
PLOS ONE (2011)
A Synthetic Biology Approach Reveals a CXCR4-G13-RhoSignaling Axis Driving Transendothelial Migration of Metastatic Breast Cancer Cells
Hiroshi Yagi et al.
SCIENCE SIGNALING (2011)
Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients
M. Lae et al.
ANNALS OF ONCOLOGY (2010)
MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells
Shawn P. Fessler et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis
Kim Pedersen et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance
Doyel Mitra et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Geldanamycin-induced down-regulation of ErbB2 from the plasma membrane is clathrin dependent but proteasomal activity independent
Nina Marie Pedersen et al.
MOLECULAR CANCER RESEARCH (2008)
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
M. M. Moasser
ONCOGENE (2007)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
Maurizio Scaltriti et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Par6-aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control
Victoria Aranda et al.
NATURE CELL BIOLOGY (2006)
The mucin muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3
Melanie Funes et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors
Shizhen Emily Wang et al.
CANCER CELL (2006)
ERBB2-mediated transcriptional up-regulation of the α5β1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions
C Spangenberg et al.
CANCER RESEARCH (2006)
The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane
C Haslekås et al.
MOLECULAR BIOLOGY OF THE CELL (2005)
The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation
H Kim et al.
ONCOGENE (2005)
FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion
N Benlimame et al.
JOURNAL OF CELL BIOLOGY (2005)
Requirements for estrogen receptor at membrane localization and function
AJ Evinger et al.
STEROIDS (2005)
Caveolin-1 in oncogenic transformation, cancer, and metastasis
TM Williams et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2005)
ErbB2 promotes Src synthesis and stability: Novel mechanisms of Src activation that confer breast cancer metastasis
M Tan et al.
CANCER RESEARCH (2005)
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas
H Shigematsu et al.
CANCER RESEARCH (2005)
Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2
SC Wang et al.
CANCER CELL (2004)
Upregulation of the catalytic telomerase subunit by the transcription factor ER81 and oncogenic HER2/Neu, Ras, or Raf
BS Goueli et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis
YM Li et al.
CANCER CELL (2004)
Regulation of the chemokine receptor CXCR4 by hypoxia
T Schioppa et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
HER2-mediated effects on EGFR endosomal sorting: Analysis of biophysical mechanisms
BS Hendriks et al.
BIOPHYSICAL JOURNAL (2003)
Muc4/Sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 to the apical surface in polarized epithelial cells
VP Ramsauer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Identification of a structural determinant necessary for the localization and function of estrogen receptor α at the plasma membrane
M Razandi et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
p38MAPK induces cell surface α4 integrin downregulation to facilitate erbB-2 -: Mediated invasion
KMW Ignatoski et al.
NEOPLASIA (2003)
A putative molecular-activation switch in the transmembrane domain of erbB2
SJ Fleishman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer
G Viglietto et al.
NATURE MEDICINE (2002)
PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest
J Liang et al.
NATURE MEDICINE (2002)
Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer
YL Chung et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Regulation of HER2/Neu promoter activity by the ETS transcription factor, ER81
DG Bosc et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2002)
ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini
SK Muthuswamy et al.
NATURE CELL BIOLOGY (2001)
p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis
HY Yang et al.
ONCOGENE (2001)
Elevated activity and expression of Src-family kinases in human breast carcinoma tissue versus matched non-tumor tissue
D Reissig et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2001)
Src family kinases and HER2 interactions in human breast cancer cell growth and survival
AP Belsches-Jablonski et al.
ONCOGENE (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
D Harari et al.
ONCOGENE (2000)
ERBIN:: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor
JP Borg et al.
NATURE CELL BIOLOGY (2000)
Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells
RM Neve et al.
ONCOGENE (2000)
ErbB2 potentiates breast tumor proliferation through modulation of p27Kip1-Cdk2 complex formation:: Receptor overexpression does not determine growth dependency
HA Lane et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Share Paper
